Wall Street Zen Upgrades Supernus Pharmaceuticals to Strong Buy

Analysts cite potential for the company's CNS therapies as key driver for upgrade.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Supernus Pharmaceuticals (NASDAQ:SUPN) has been upgraded from a "buy" rating to a "strong-buy" rating by equity research firm Wall Street Zen. The upgrade comes as analysts see potential for the company's central nervous system (CNS) therapies, including its extended-release antiepileptic medications Trokendi XR and Oxtellar XR, as well as its recently approved ADHD treatment Qelbree.

Why it matters

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing CNS therapies. The upgrade from Wall Street Zen reflects growing confidence in the company's product portfolio and pipeline, which could signal increased investor interest and potential upside for the stock.

The details

In its research note, Wall Street Zen cited the strong performance of Supernus' existing products and the potential for its pipeline, including Qelbree, to drive future growth. The upgrade comes after several other analysts have weighed in on the stock, with some maintaining a "hold" rating and others issuing "sell" recommendations.

  • Supernus Pharmaceuticals stock opened at $54.73 on Friday, February 28, 2026.
  • The company's shares have traded in a range of $29.16 to $59.68 over the past 52 weeks.

The players

Supernus Pharmaceuticals

A specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies, including extended-release antiepileptic medications and an ADHD treatment.

Wall Street Zen

An equity research firm that has upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The upgrade from Wall Street Zen reflects growing confidence in Supernus Pharmaceuticals' ability to capitalize on the market potential of its CNS therapies, particularly its recently approved ADHD treatment Qelbree. This could signal increased investor interest and potential upside for the stock.